Alpha Tau Medical notifies availability of press release on Alpha DaRT-pembrolizumab head and neck cancer data
DRTS•Alpha DaRT-pembrolizumab head and neck cancer data
Alpha Tau posted a new release on Alpha DaRT with pembrolizumab in locally advanced or metastatic head and neck cancer.
- Nine evaluable patients showed a 100% objective response rate; 4 complete responses.
- Median overall survival was 18.2 months; median progression-free survival was 5.4 months.
- No Alpha DaRT-related serious adverse events; 2 Grade 1 adverse events reported.
- Full release: link.
